Comparative Anti-Hypertensive Effectiveness of β-Adrenoreceptor Antagonists with Different Pharmacological Properties: Dose—Response Studies during Acute and Chronic Administration

1976 ◽  
Vol 51 (s3) ◽  
pp. 541s-544s
Author(s):  
S. H. Taylor ◽  
C. Davidson ◽  
W. Singleton ◽  
U. Thadani

1. Immediate and long-term blood pressure-lowering activity of five β-adrenoreceptor antagonists with different ancillary pharmacological properties were compared in a randomized double-blind placebo controlled factorial trial in twenty-five previously untreated patients with stable uncomplicated essential hypertension. 2. In doses which produced similar reductions in exercise tachycardia, all drugs exerted similar antihypertensive activity, which was greater on systolic than diastolic pressure and greatest during exercise. 3. These effects were maximum within an hour and lasted for over 8 h after a single oral dose. 4. Blood pressure-lowering activity, particularly the reduction in exercise systolic pressure, was significantly related to the logarithm of the dose of each drug. 5. Anti-hypertensive activity was maximally enhanced after 4 weeks of sustained treatment at any given dose. There was no short-term habituation to treatment and substitution with placebo resulted in a return of the blood pressure to pretreatment values within 4 weeks without subsequent overshoot. 6. The blood pressure-lowering activity of these drugs was predominantly related to their common property of competitive antagonism of cardiac β-adrenoreceptors; their ancillary pharmacological properties, with the exception of intrinsic vasodilator activity, played little part in this response.

1975 ◽  
Vol 64 (8) ◽  
pp. 1423-1425 ◽  
Author(s):  
Samir M. El-Antably ◽  
Taito O. Soine ◽  
Nadim A. Shaath ◽  
Prem K. Guptat

1988 ◽  
Vol 36 (3) ◽  
pp. 1000-1006 ◽  
Author(s):  
KYOKO ADACHI ◽  
HIROAKI NANBA ◽  
MASAMICHI OTSUKA ◽  
HISATORA KURODA

2004 ◽  
Vol 92 (4) ◽  
pp. 701-706 ◽  
Author(s):  
Beate Turner ◽  
Christian Mølgaard ◽  
Peter Marckmann

Recent studies have cast doubt on the proposed lipid-lowering and blood pressure-lowering effects of garlic. We tested the effect of dried garlic (Allium sativum) powder on blood lipids, blood pressure and arterial stiffness in a 12-week randomised, double-blind, placebo-controlled trial. Seventy-five healthy, normo-lipidaemic volunteers (men and women aged 40–60 years) were assigned to dried garlic powder tablets (10·8 mg alliin (3-(2-propenylsulfinyl)-l-alanine)/d, corresponding to about three garlic cloves) or placebo. Sixty-two subjects were eligible for the per-protocol analysis. The primary outcome measure was serum total cholesterol concentration. Secondary outcome measures were LDL-cholesterol, HDL-cholesterol and triacylglycerol concentrations, blood pressure and arterial stiffness (assessed by pulse wave velocity). No significant differences between the garlic and placebo groups were detected for any of the outcome measures. However, garlic powder was associated with a near-significant decrease (12 %) in triacylglycerol concentration (P=0·07). In conclusion, garlic powder tablets have no clinically relevant lipid-lowering and blood pressure-lowering effects in middle-aged, normo-lipidaemic individuals. The putative anti-atherosclerotic effect of garlic may be linked to risk markers other than blood lipids.


2021 ◽  
Vol 6 (1) ◽  
pp. 337-359
Author(s):  
Ardiansyah ◽  
◽  
Fauziyyah Ariffa ◽  
Rizki Maryam Astuti ◽  
Wahyudi David ◽  
...  

2018 ◽  
Vol 32 (6) ◽  
pp. 1073-1079 ◽  
Author(s):  
Fatemeh Homayouni ◽  
Fatemeh Haidari ◽  
Mehdi Hedayati ◽  
Mehrnoosh Zakerkish ◽  
Kambiz Ahmadi

2018 ◽  
Vol 101 (4) ◽  
pp. 2819-2825 ◽  
Author(s):  
Lilia M. Beltrán-Barrientos ◽  
Aarón F. González-Córdova ◽  
Adrián Hernández-Mendoza ◽  
Eduardo H. Torres-Inguanzo ◽  
Humberto Astiazarán-García ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document